Congenital hypogonadotropic hypogonadism (CHH) and its anosmia-associated form (Kallmann syndrome [KS]) are genetically heterogeneous. Among the >15 genes implicated in these conditions, mutations in FGF8 and FGFR1 account for~12% of cases; notably, KAL1 and HS6ST1 are also involved in FGFR1 signaling and can be mutated in CHH. We therefore hypothesized that mutations in genes encoding a broader range of modulators of the FGFR1 pathway might contribute to the genetics of CHH as causal or modifier mutations. Thus, we aimed to (1) investigate whether CHH individuals harbor mutations in members of the so-called ''FGF8 synexpression'' group and (2) validate the ability of a bioinformatics algorithm on the basis of protein-protein interactome data (interactome-based affiliation scoring [IBAS]) to identify high-quality candidate genes. On the basis of sequence homology, expression, and structural and functional data, seven genes were selected and sequenced in 386 unrelated CHH individuals and 155 controls. Except for FGF18 and SPRY2, all other genes were found to be mutated in CHH individuals:
Introduction
Congenital hypogonadotropic hypogonadism (CHH [MIM 146110]) due to gonadotropin-releasing hormone (GnRH) deficiency and/or resistance is a rare genetic disorder characterized by abnormal pubertal development and infertility.
1 CHH is often associated with anosmia and is then We have documented a lack of GnRH neurons in the hypothalamus of Fgf8 hypopmorphic mice, which underscores the exquisite sensitivity of the GnRH neuronal population to FGF8 signaling. 5 Subsequent studies have established FGF8 as a critical morphogen for GnRH neuron fate specification, as well as for the development of the olfactory system. 6 Other tissues patterned by FGF8 include the ears, eyes, kidneys, and limbs, [7] [8] [9] [10] all of which can be affected in CHH.
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KAL1 (Kallmann syndrome 1 sequence [MIM 300836]) and HS6ST1 (heparan sulfate 6-O-sulfotransferase 1 [MIM 604846]), two genes known to be mutated in CHH, also encode important components of FGF8-FGFR1 signaling. KAL1, the first gene discovered to harbor mutations in KS, 12 ,13 encodes anosmin-1, which enhances FGF signaling by direct physical interactions with the FGFR-FGF-heparan sulfate proteoglycan (HSPG) complex on the cell surface. 14 HS6ST1, which encodes a heparan sulfotransferase enzyme, was identified as a gene mutated in CHH on the basis of a C. elegans study demonstrating that heparan 6-O-sulfation was required for anosmin-1 function in vivo. 15 The fact that multiple genes encoding components of the FGF pathway are already known to be mutated in CHH (e.g., KAL1, HS6ST1, FGF8 and FGFR1) led us to hypothesize that a broader survey of the FGF network might uncover additional mutated genes. Expression data from diverse organisms have identified a cluster of genes that are similarly expressed and regulated during development, and these are collectively referred to as ''the FGF8 synexpression group.'' [16] [17] [18] These genes not only show spatiotemporal expression patterns similar to that of FGF8 but also specifically modulate the signaling efficiency of FGF8 through FGFR1 as enhancers or inhibitors (Table 1 16,18-36 and Figure 1A ). We therefore consid- [16] [17] [18] (Table 1 and Figure 1A ). We also selected FGF17 (fibroblast growth factor 17 [MIM 603725]) and FGF18 (fibroblast growth factor 18 [MIM 603726]) because of their high homology to FGF8 (with which they encode the so-called ''FGF8 subfamily'' of fibroblast growth factors [FGFs] ), 37 their coexpression with
Fgf8 in the olfactory placode, and their shared ability to signal through FGFR1c 37 (Table 1 and Figure 1A ).
Thus, the primary objective of this study was to investigate whether CHH individuals harbor mutations in genes encoding members of the extended FGF8-FGFR1 network. A secondary objective was to validate the ability of a bioinformatics tool on the basis of protein-protein interactome data to identify high-quality candidate genes and to prioritize them for experimental confirmation.
Subjects and Methods

Subjects
CHH was diagnosed and classified as KS or normosmic idiopathic hypogonadotropic hypogonadism (nIHH) according to standard criteria. 38 A cohort of 386 CHH individuals included 199 KS individuals (152 men and 47 women) and 187 nIHH individuals (140 men and 47 women). Several CHH probands harbored mutations in genes previously identified to be associated with nIHH and/or KS:
(NMDA receptor synaptonuclear signaling and neuronal migration factor, formerly known as
, and TAC3 (n ¼ 1). 15, [39] [40] [41] [42] Also included was a control group of 155 unaffected subjects of European descent (83 men and 72 women) with normal reproductive function. The study was approved by the human research committee of Massachusetts General Hospital, and all subjects provided written informed consent prior to participation.
DNA Sequencing
Genomic DNA was extracted from peripheral-blood samples. The coding exons and proximal introns (R15 bp from splice sites) of FGF17 (five exons), FGF18 (five exons), IL17RD (13 exons), DUSP6 (three exons), SPRY2 (two exons), SPRY4 (two exons), and FLRT3 (one exon) were amplified by PCR and determined by direct sequencing. Each gene's sequence was identified with the use of the UCSC and ENSEMBL genome databases. All DNA variants were found on both DNA strands and were confirmed in a separate PCR. Genes and proteins are described according to HGVS nomenclature. A variant was considered a mutation if it had a minor allele frequency (MAF) < 1% in unaffected controls (which includes ''disease-only'' variants with MAF ¼ 0% in controls) and in the 1000 Genomes data set and if it altered a conserved amino acid or/and was predicted to cause loss of function by at least one prediction program (PolyPhen-2, 43 SIFT, interaction between a Cp and the PCPs is significant, a Cp is determined to be associated with the F on the basis of its interactome; hence, we named the method interactome-based affiliation scoring (IBAS). Interactome data come from a well-established human protein interaction network (InWeb) of~430,000 proteinprotein interactions among 12,507 human proteins (InWeb [48] [49] [50] ).
In this work, the PCPs are 14 proteins encoded by genes known to be involved in GnRH deficiency: GNRH1, GNRHR, PROK2, PROKR2, KAL1, FGF8, FGFR1, TAC3, TACR3, KISS1, KISS1R, HS6ST1, CHD7 (chromodomain helicase DNA binding protein [MIM 608892]), and PCSK1 (proprotein convertase subtilisin/ kexin type 1 [MIM 162150]). First, IBAS was trained, parameter optimized, and validated on this set of known PCPs for the identification of the optimal set of parameters that could predict the PCPs among random proteins. In a standard leave-one-out crossvalidation, the PCPs predicted each other with an area under the receiver-operating-characteristic curve of 0.8 (p < 0.002 with a permutation test). This allowed all candidates (i.e., 12,493 proteins covered by interaction data, excluding PCPs 1-14 in InWeb) to be scored and ranked, and permutation tests were used for determining the significance of the observed scores. IBAS will be presented in a separate paper in fuller detail, including a discussion of confounding factors, permutation strategies, and applications to data types, such as next-generation sequencing (K. Lage, unpublished data).
Functional Analyses of IL17RD Mutations
The ability of altered IL17RD proteins to inhibit FGF8 signaling was assessed in human embryonic kidney (HEK) 293 cells. The long form of human IL17RD-encoding cDNA (RefSeq accession number NM_017563) was subcloned into vector pcDNA3.1(þ) (Invitrogen, Carslbad, CA, USA), and altered proteins were generated by site-directed mutagenesis. HEK293 cells were transiently transfected in 24-well plates at 40% confluency with 5 ng wildtype (WT) FGFR1c and 20 ng WT or altered IL17RD together with 5 ng AP-1 luciferase reporter (Stratagene, La Jolla, CA) and 170 ng empty vector (EV) with the use of FuGene6 reagent (Roche Diagnostics). AP-1 is activated by the mitogen-activated protein kinase (MAPK) downstream of FGFR1. 51 We avoided using constituvely active internal control reporters (such as pRL-TK or pRL-SV40) to correct for variations in transfection efficiency because they are responsive to FGFs. 52 
Functional Analyses of FGF17 Mutations
Expression and Purification of WT and Altered FGF17 Ligands Bacterially expressed WT FGF17 and p.Ile108Thr, p.Arg177His, and p.Asn187Ser altered FGF17 were refolded in vitro and purified by heparin affinity chromatography; size-exclusion chromatography was subseqntly performed at 4 C according to a published protocol. 5 The purification yield of the p.Ile108Thr altered protein was significantly less than that of the WT as a result of its precipitation during refolding and purification; this is in agreement with the prediction that the p.Ile108Thr substitution destabilizes the b-trefoil core of FGF17.
Surface-Plasmon-Resonance Spectroscopy
Physical interactions between the ligand-binding region (D2-D3 fragment) of human FGFR1c and WT or p.Arg177His altered FGF17 were analyzed by surface-plasmon-resonance (SPR) spectroscopy with a BIAcore 2000 system (GE Healthcare) as previously described. 37 WT FGF17, p.Arg177His altered FGF17, and FHF1b Increasing concentrations (100 nM to 3.2 mM) of the analyte (D2-D3 fragment of FGFR1c) were prepared in HBS-EP buffer and were passed over the channels containing the immobilized ligands at 50 ml/min, and the association phase of FGF17-FGFR1c interaction was monitored for 180 s. Thereafter, HBS-EP buffer was passed over the chip for 180 s for observation of the dissociation phase. Between analyte injections, the sensor surface was regenerated by 35 ml of 2.5 M NaCl in 5 mM HEPES (pH 7.5). Sensorgrams were processed in BIAevaluation software v.4.1.1.
Cell-Based Assays FGF17-stimulated signaling activity was assessed in L6 myoblast cells as previously described. 5, 53 In short, cells were transiently transfected with WT or altered FGFR1c expression vector in combination with the osteocalcin-FGF-response-element luciferase reporter. Cells were treated with increasing doses of WT or altered FGF17 and assayed for luciferase activity as described. The data were plotted and fitted with four-parameter sigmoidal doseresponse curves with Prism software (version 5; GraphPad). Transfection experiments were performed in triplicate and repeated three times. Individual experiments were expressed as a percentage of the WT, and the mean maximal activity from three independent experiments was compared to that of the WT by a Student's t test. Data are presented as the mean 5 SEM.
Mouse Studies
Mice were housed and handled in accordance with the Institutional Animal Care and Use Committee of the University of Colorado at Boulder. Mice homozygous for a hypomorphic Fgf8 allele 54 and WT controls were obtained from the breeding of heterozygotes. For double GnRH and IL17RD immunohistochemistry (IHC), embryonic day (E) 10.5-E12.5 embryos were removed and fixed by immersion in 4% paraformaldehyde for 6 hr, cryoprotected in 30% sucrose, and cut on a cryostat. Thaw-mount sections (20 mm) were collected and processed for IHC with rabbit antiGnRH antiserum LR5 (gift from R. Benoit, Montreal General Hospital) followed by goat anti-Il17rd antiserum (R&D Systems, Minneapolis, MN, USA). Secondary antibodies conjugated with different fluorophores were used for fluorescence labeling. For single GnRH IHC, E13.5 embryos and postnatal day (P) 0 brains were fixed, cryoprotected and sectioned as above, and processed as described. 55 Fgf17 whole-mount RNA in situ hybridization (WM-ISH) was performed on Fgf8 hypomorphic and WT mice as described 56 with a 679 nt digoxigenin-labeled Fgf17 antisense riboprobe.
Assessment of Oligogenicity
In the same individual, the simultaneous presence of mutations in different disease-associated genes (oligogenicity) was evaluated for all subjects of European descent (350 CHH individuals and 155 controls) as described previously. 39 Each subject was scored as to the total number of alleles harboring mutations. In subjects with more than a single allele with such mutations (biallelic or triallelic), it was further noted whether these mutations were on alleles of the same or different genes (monogenic or oligogenic, respectively) by the sequencing of individual alleles after the cloning of PCR amplicons encompassing the mutations in the pTOPO vector (Invitrogen). Oligogenicity was compared between CHH individuals and controls by a Fisher's test.
Results
FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 Harbor Mutations in CHH Individuals
We sought mutations by Sanger sequencing in genes belonging to the FGF8 subfamily (FGF17 and FGF18) and the FGF8 synexpression group (IL17RD, DUSP6, SPRY2, SPRY4, and FLRT3) among 386 CHH probands (199 KS and 187 nIHH) and 155 controls. This functional candidate-gene approach was fruitful in yielding mutations among CHH probands in five of seven genes screened, and each individual gene contributed to a small percentage of cases (1%-4%) ( Figure 1A and Table S1 , available online). The genotypes and phenotypes of the CHH probands with mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are summarized in Table 2 ; individuals carrying functionally characterized mutations in FGF17 or IL17RD are presented in more detail below. Taking into account the previously described CHH-associated mutated genes that also belong to the FGF8 module (FGFR1, FGF8, KAL1, and HS6ST1) (Tables S1 and S2 ), 23% (91/386) of CHH probands harbored mutations in at least one gene associated with the FGF network; 74% (67/91) of these had KS ( Figure 1B ).
IBAS Identifies IL17RD and FGF17 as the Top CHH Candidate Genes
A bioinformatics method (IBAS) was independently utilized for identifying and prioritizing candidate CHH genes. The protein-protein interactome-based algorithm trained on the set of proteins encoded by the genes known to be mutated in CHH identified 35 proteins with a posterior probability [PP] score > 0.32 ( Figure 2 and Table S5 ). We estimated the empirical probability of observing a PP R 0.32 by ranking all 12,507 proteins in InWeb by using 500 random models to obtain a null distribution of random PPs; this indicated that a PP R 0.32 is highly significant at p < 1/500 ¼ 0.002. In a comparison between the ranked list and the sequencing results, it was notable that IL17RD had the highest PP and that FGF17 had the second-highest PP; in constrast, DUSP6, SPRY4, and FLRT3 were not among the top 35 proteins. Therefore, IL17RD and FGF17 were selected among the five mutation-harboring genes for functional characterization of the mutants and further experimental validation.
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Mutations in IL17RD Are Associated with KS and a High Frequency of Hearing Loss Clinical data on the eight unrelated CHH probands harboring missense heterozygous and homozygous IL17RD mutations are summarized in Table 2 and Figure 3B . Notably, all have KS; 7/8 have absent puberty, and 6/8 exhibit congenital hearing loss, which is unilateral in most (5/8). In fact, the two probands without hearing loss (II-1 in F1 and II-2 in F2) carry the same c.392A>C (p.Lys131Thr) mutation ( Figure 3B ). In two pedigrees with hearing loss, the probands (II-4 in F4 and II-2 in F7) carry homozygous IL17RD mutations; the parents, who are known or assumed to carry one mutant allele, display neither hearing loss nor hypogonadism ( Figure 3B ). In two other pedigrees, the probands (II-2 in F5 and II-3 in F8), who are the only family members with hearing loss, demonstrate apparently oligogenic inheritance: a heterozygous IL17RD mutation plus a heterozygous FGFR1 or KISS1R mutation. Pedigree F5 indicates that the heterozygous IL17RD mutation is insufficient to cause hearing loss, given that the proband's mother (I-2), who carries the IL17RD, but not the FGFR1, mutant, has normal hearing. Lastly, hearing loss does not cosegregate with the IL17RD mutation in pedigree F6, given that the proband's fraternal twin (II-4) has hearing loss without the mutation and their mother (I-2) carries the mutation but has normal hearing ( Figure 3B ). Collectively, these data indicate that IL17RD mutations are strongly associated with KS and hearing loss; however, one allelic defect is most likely not sufficient, meaning that additional affected alleles in the same and/or other genes must be present to create the phenotype of KS with hearing loss.
Functional Characterization of the CHH-Associated IL17RD Mutations All IL17RD mutations were predicted to be pathogenic in three out of four prediction programs; the only exception was c.485A>G (p.Lys162Arg), which was predicted to cause loss of function by only one program (Table S1 ). Because IL17RD is an inhibitor of FGF signaling ( Figure 1A) , loss of IL17RD function is expected to lead to higher FGF-pathway activity. The functional effect of the identified mutations ( Figure 3A ) on FGF signaling was tested in a cell-based reporter-gene assay. Cells expressing WT FGFR1c alone elicited a 3-fold increase in the activity of the AP-1 luciferase reporter when treated with FGF8b ( Figure 3C ), whereas, similarly to untreated cells, cells coexpressing WT IL17RD exhibited markedly lower activity (70% inhibition). For a negative control, we employed a truncated IL17RD form (D326) that lacks the entire intracellular domain 57 and fails to inhibit FGF8 downstream signaling. The p.Lys131Thr, p.Pro306Ser, and p.Ser468Leu altered IL17RD proteins inhibited FGF8 signaling to a significantly lesser degree than did WT IL17RD (89%, 67%, and 32% relative to WT, respectively; p < 0.05) ( Figure 3C ), indicating loss of function; the p.Tyr379Cys and p.Pro577Gln altered proteins also demonstated reduced inhibitory activity (75% and 82% relative to WT, respectively), which approached significance (p ¼ 0.06) ( Figure 3C ). The p.Lys162Arg and p.Ala735Val altered proteins behaved similarly to WT IL17RD in this assay ( Figure 3C ). Overall expression levels of the altered proteins were similar to that of the WT (Figures S2A and  S2B ). The mature IL17RD fraction of p.Lys131Thr and p.Lys162Arg was increased compared to that of the WT (122% and 105%, respectively; p < 0.05) ( Figure S2C ), whereas that of p.Ser468Leu was decreased (80% relative to WT; p < 0.05). The p.Lys131Thr, p.Lys162Arg, and p.Ala735Val altered proteins all exhibited significantly decreased cell-surface expression than did the WT (~15%, p < 0.05), whereas that of the p.Ser468Leu altered protein was~50% of that of the WT (p < 0.05) ( Figure S2D ). The other altered proteins (p.Pro306Ser, p.Tyr379Cys, and p.Pro577Gln) had cell-surface expression similar to that of the WT ( Figure S2D ).
FGF8 Is Required for IL17RD Localization in the Olfactory Placode
To link IL17RD to GnRH neuron fate specification and migration, we investigated the localization patterns of IL17RD and GnRH in the nasal region of mouse embryos at E10.5-E12.5. IL17RD immunoreactivity was highest in the E10.5 epithelium of the developing olfactory placode, where FGF8 is present, whereas it was much milder in the mesenchyme ( Figure 3D , left panel). 19 IL17RD localized to the perinuclear compartment of the cell ( Figure 3D , right panel). 58 At E12.5, IL17RD reactivity was no longer detectable in the olfactory epithelium ( Figure 3E , lower inset) but 
Abnormal dentition includes abnormal development of teeth or crowded, extra, or missing teeth. Low bone mass includes osteopenia, osteoporosis, or fractures. Abbreviations are as follows: Dx, diagnosis; S, sporadic; F, familial; P, partial; A, absent (absent puberty is defined as testicular volume % 3 ml or primary amenorrhea at presentation); and NA, not assessed. was detected in the septal area and in the midbrain-hindbrain junction ( Figure 3E ). IL17RD was undetectable in the brain of Fgf8 hypomorphic embryos. We also evaluated localization patterns of IL17RD and GnRH at E11.5, when GnRH neurons begin migrating from the olfactory placode to the developing olfactory bulb. In these mice, IL17RD levels were dramatically decreased overall relative to E10.5 mice, yet IL17RD was present in a few GnRH neurons ( Figure S2E) . Cumulatively, these studies suggest that IL17RD might have a role in the early stages of GnRH neuron fate specification.
A KS-Associated FGFR1 Mutation Implicates FGF17 as a Ligand Involved in GnRH Biology FGF17 shares 61% overall sequence identity with FGF8b, signals through FGFR1c, and exhibits the same receptorbinding-specificity profile as FGF8b. 37 The association between FGF8b mutations and KS was based on the discovery of a heterozygous FGFR1c mutation, c.1025T>C (p.Leu342Ser), in a KS individual in whom FGF8b binding was abolished in transfected cells. 53 The p.Leu342Ser altered FGFR1c maps to a hydrophobic groove that is conserved in the D3 of FGFR1c, FGFR2c, FGFR3c, and FGFR4 and is specifically contacted by FGF8 subfamily members. Given the homology between FGF17 and FGF8b, we demonstrate that p.Leu342Ser also abolishes FGF17-stimulated signaling through FGFR1c ( Figure 4A ). These data suggest that FGF17 might be implicated in GnRH neuron biology as an alternative ligand to FGF8b. (E) Widefield epifluorescence images of IL17RD immunoreactivity (red) and nuclear marker DAPI (blue) in E12.5 mouse ventral forebrain (sagittal view) of WT (left) and homozygous Fgf8 hypomorphic (right) embryos illustrate the complete absence of IL17RD in Fgf8 hypomorphic embryos. IL17RD immunoreactivity was high in the septal area and in the midbrain-hindbrain junction of the WT embryo (upper inset) and nearly undetectable in the olfactory epithelium, where migrating GnRH neurons (green) in the developing nasal regions are localized (lower inset). Scale bars represent 100 mm for all images except the insets, in which they represent 50 mm. Abbreviations are as follows: cb, cerebellum; GE, ganglionic eminence; SA, septal area; and oe, olfactory epithelium; and Sef, similar expression as FGF (former name of IL17RD).
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Functional Characterization of the CHH-Associated FGF17 Mutations Three unrelated CHH probands harbor heterozygous mutations in FGF17 ( Figures 4B and 5A) , and their clinical data are summarized in Table 2 . Given the strong sequence identity between FGF8b and FGF17 and their similar receptor-binding-specificity profiles, we employed the previously established FGF8b-FGFR2c structure (Protein Data Bank ID 2FDB) 37 to model the mutations' impact. FGF17
Arg177 is conserved in FGF8 (Arg177) ( Figure S1 ); in the FGF8b-FGFR2c structure, it forms a hydrogen bond with Asp247 in D2 of FGFR2c. Moreover, the D2 domains of FGFR2c and FGFR1c share strong sequence homology, and FGFR2c Asp247 is conserved in FGFR1c. On the basis of these structural data, it is predicted that the p.Arg177His altered FGF17 cannot form this hydrogen bond and thus has reduced binding to FGFR1c ( Figure 4C ). FGF17 Ile108 is also conserved in FGF8b ( Figure S1 ), and in the FGF8b-FGFR2c structure, its side chain makes hydrophobic interactions with Met151, Val65, Val67, Val99 (Ile99 in FGF17), Leu86, Ile73, and Phe129 in the hydrophobic interior core. Hence, Ile108 is key for the stability of the b-trefoil core of FGF17 and FGF8. The p.Ile108Thr substitution is predicted to weaken these hydrophobic interactions in the FGF17 core region and to thereby render the mutant ligand less thermally stable and thus prone to unfolding ( Figure 4D ). The individual harboring the FGF17 mutation, c.323T>C (p.Ile108Thr), also carries FGFR1 c.749G>A (p.Arg250Gln), as well as other mutations in genes associated with the FGF8 network (described below). Arg250 is located in the FGFR1c D2-D3 linker region, which is invariably conserved among human FGFRs; Arg250 is pivotal in FGF-FGFR binding affinity through conserved hydrogen bonds with FGF ligands, including FGF8. The p.Arg250Gln substitution is predicted to impair the ability of FGFR1c to bind FGF17. On the other hand, the p.Asn187Ser alteration maps to the C-terminal tail of FGF17 and is predicted to have no impact on FGF17 function.
Consistent with the structural predictions, SPR data showed that the p.Arg177His altered FGF17 exhibited negligible binding to FGFR1c ( Figure 4E ). Moreover, the p.Arg177His altered FGF17 had dramatically reduced ability to activate FGFR1c ( Figure 4F) ; the p.Ile108Thr altered FGF17 was also defective in FGFR1c activation, whereas the p.Asn187Ser altered FGF17 was indistinguishable from the WT ( Figure 4F ). Finally, the p.Arg250Gln altered FGFR1c caused severe loss of function ( Figure 4G ). Because the FGFR1c c.749G>A (p.Arg250Gln) and FGF17 c.323T>C (p.Ile108Thr) mutations co-occur in the same individual, we exposed cells expressing the altered receptor to the altered ligand; relative to WT FGF17, the p.Ile108Thr FGF17 completely failed to activate the p.Arg250Gln FGFR1c, indicating that these two loss-of-function substitutions act in an additive fashion ( Figure 4G ).
FGF8 Is Required for Fgf17 Expression in the Olfactory Placode
To link Fgf17 to GnRH biology, we examined its expression pattern in the nasal cavity of mouse embryos through WM-ISH at E10.5, when GnRH neuron fate specification occurs. Fgf17 was robustly expressed in regions where Fgf8 is known to be highly expressed: the commissural plate ( Figures 4H1 and 4H3) , the midbrain-hindbrain junction ( Figure 4H1 ), and the medial olfactory placode ( Figure 4H3 ), where GnRH neurons emerge. 19 Importantly, there was hardly any Fgf17 expression in Fgf8 hypomorphic mice ( Figures 4H2 and 4H4 ), suggesting that Fgf17 should be considered a member of the Fgf8 synexpression group.
Mutations in FGF8-Network-Associated Genes
Contribute to Oligogenic CHH To assess oligogenicity, we investigated a subset of individuals comprising all European-descendent probands (n ¼ 350/386) and controls (n ¼ 155/155) screened for the nine genes associated with the FGF pathway. Seventeen genes were analyzed (the nine genes encoding members of the FGF network [ Figure 1A ] and eight others: PROKR2, PROK2, KISS1R, GNRHR, GNRH1, TAC3R, TAC3, and NSMF). We identified mutations in 35% of probands (124/350) (Table S3) . Nearly all mutations in the 17 genes cause loss of function in vitro and/or are predicted in silico to be deleterious (Table S1) . [39] [40] [41] [59] [60] [61] [62] Notably, 69% (86/ 124) of these CHH probands harbor at least one mutation within the genes encoding members of the FGF network (Table S3) , highlighting the major contribution of mutations affecting this pathway to the genetic architecture of CHH. Of the 124 probands harboring mutations, 14 carry biallelic mutations in the same gene (i.e., 11% homozygosity or compound heterozygosity) and 24 carry at least two mutant alleles from different genes (i.e., 19% oligogenicity; 95% confidence interval: 12%-26%) (Figures 5B and  5C and Tables 3 and S3 ). In 23/24 cases, the oligogenic interactions include at least one gene associated with the FGF network ( Figure 5B and Table 3 ). Among the controls, 16% (25/155) harbor missense mutations; each subject carries a single heterozygous mutation (Table S4) . Four mutations (with MAF < 1% in controls) within genes encoding components of the FGF network are also present in the CHH cohort (Table S4) : FGF8 c.77C>T (p.Pro26Leu), IL17RD c.392A>C (p.Lys131Thr), KAL1 c.1759G>T (p.Val587Leu), and SPRY4 c.722C>A (p.Ser241Tyr) (Table S4) . Notably, most CHH probands harboring a mutation present in the control population also carry an additional gene defect. This is consistent with the fact that oligogenicity was found only in probands and never in controls (24/350 versus 0/155, p ¼ 0.0003; Figure 5C ); biallelic mutations (homozygous or compound heterozygous) were also more frequent in probands than in controls (14/350 versus 1/155, p ¼ 0.04; Figure 5C ). The female KS individual ( Figure 5A , X-2 in family 9). She had primary amenorrhea (successfully treated with pulsatile GnRH, resulting in ovulation), severe osteoporosis (Z score ¼ À3) with multiple fractures, surgery for bilateral genu valgus, and severe obesity and developed type 2 diabetes before 40 years of age. The proband is part of a large French Canadian family (previously described in great detail) with several loops of consanguinity and in which 27% of family members exhibit CHH. 63 Interestingly, our genetic analysis revealed that all affected subjects in this pedigree harbor a loss-of-function FGFR1 c.749G>A (p.Arg250Gln) mutation, as well as other mutations in genes associated with the FGF network: each affected CHH family member (IX-1, IX-6, X-2, and X-5 in family 9) carries three to six mutant alleles among four different FGF-network-associated genes (FGF17, FLRT3, HS6ST1, and FGFR1), whereas asymptomatic family members (IX-2, IX-3, IX-4, IX-5, IX-7, and X-4 in family 9) harbor zero to two mutant alleles. In another notable case of oligogenicity, the KS proband ( Figure 3B , F5 II-2) harbors a loss-of-function heterozygous c.1136A>G (p.Tyr379Cys) IL17RD mutation inherited from her anosmic mother (I-2 in F5). However, the female proband also harbors a de novo heterozygous c.1042G>A (p.Gly348Arg) FGFR1 mutation that is predicted to cause loss of function by all four in silico prediction programs (Table S1 ). This combination manifested in the proband with a severe phenotype including KS with dental agenesis, hearing loss, osteoporosis, and a complete absence of puberty.
Discussion
In this work, we identify mutations in five genes encoding components of the FGF pathway (FGF17, IL17RD, SPRY4, DUSP6, and FLRT3) in CHH individuals. All together, 27 mutations were found in 30 unrelated CHH probands, and mutations in each gene accounted for 1%-4% of CHH cases. Together with the other FGF-network-associated genes previously known to be mutated in CHH (FGFR1, FGF8, KAL1, and HS6ST1), 23% (90/386) of CHH individuals have at least one mutation affecting the FGF pathway, indicating a major contribution of this network to GnRH ontogeny. The majority of probands display olfactory defects, consistent with the critical role of the FGF8 synexpression group in early stages of GnRH neuron development. Traditionally, the average success rate of candidate-gene approaches in CHH is~30%; 3 70% of the screened candidate genes associated with the expanded FGF network had mutations. There were two orthogonal components to the successful strategy: (1) focus on the ''FGF8 synexpression group'' and (2) utilization of a bioinformatics algorithm for gene prediction and prioritization. Genes that are ''synexpressed'' with FGF8 share a similar spatiotemporal expression with FGF8 during development, and the proteins they encode specifically modulate the efficiency of FGF8 signaling through FGFR1c ( Figure 1A) . [16] [17] [18] Alterations in the modulators (inhibitors or activators) of FGF8 most likely disrupt the fine-tuning of FGF8 signaling, leading to abnormal development of GnRH neurons and the olfactory system. The mechanisms by which altered FGF8 signaling impacts GnRH neuron fate specification are not well understood, largely because no marker for GnRH neuron progenitors is known. Still, it is known that FGF8 is a potent cell-survival factor during early neural development in the forebrain and the midbrain-hindbrain boundary, as well as for migrating neural crest and olfactory stem cells. 64 Consistently, Fgf8-conditional-knockout mice exhibit increased levels of apoptosis in the developing olfactory epithelium (OE) between E10.5 and E12.5; 65 thus, decreased FGF8 signaling might lead to premature elimination of GnRH progenitor cells. Recently, FGF8 was shown to maintain the geneexpression signatures and proliferative identities of two precursor classes in the OE: MEIS-positive cells (which reside in the lateral OE) and SOX2-and ASCL1-positive cells (which reside in the medial OE). Thus, decreased FGF8 signaling might hamper progenitor cells from becoming GnRH neurons. 66 The second component to the strategy applied was an unbiased approach to identifying high-quality candidate genes by analyzing the interactome of proteins encoded by genes known to be mutated in CHH independently of the synexpression data. Among the entire proteome, the IBAS algorithm awarded significant scores to a small set of 36 proteins, among which IL17RD and FGF17 were the top ranked. Although one might intuitively expect that proteins related to FGFR1-FGF8 signaling would score well in IBAS, such results were not observed for other receptor-ligand pairs associated with CHH. In fact, the FGF8-associated proteins were awarded high scores because they have been shown to have high-quality, specific interactions with FGFR1 and/or FGF8. Because FGFR1 has >300 annotated interaction partners in InWeb, it was not itself awarded a significant IBAS score because the likelihood of interacting directly with 1/14 CHH-associated proteins (in this case, FGF8) given a total of 300 annotated interaction partners is not significant. Thus, the identification by IBAS of IL17RD and FGF17 as the top two candidates, matching the results of the genetic analysis, indicates that IBAS is a powerful methodology for genome-scale candidate prioritization. IBAS, along with many more details, will be made broadly available as a community resource (K. Lage, unpublished data).
The top protein prioritized by IBAS (IL17RD) was validated by the identification of homozygous and heterozygous mutations in KS probands. IL17RD is a single transmembrane glycoprotein with sequence similarity to the intracellular domain of the interleukin-17 receptor; it is one of the major antagonists of FGF downstream signaling in vivo 16, 18 and in vitro. 57, 58 The mechanisms by which IL17RD inhibits FGF signaling are contentious because it has been shown to act both at the level of the FGF receptors (FGFR1 and FGFR2) 18 and on downstream components of the Ras-ERK1/2 pathway by capturing active MEK and ERK complexes at the Golgi apparatus and inhibiting their dissociation. 16, 58 Close spatiotemporal interdependence between FGF signaling and IL17RD expression has been reported in various mammalian tissues. 67 Here,
we document high IL17RD expression in the olfactory epithelium at E10.5, coinciding with the timeframe of GnRH neuronal fate specification, which is dependent on FGF8. The coexpression of IL17RD with FGF8 in the olfactory placode during embryogenesis suggests a potential role in the early development of both GnRH and olfactory neurons. Notably, most of the IL17RD mutations identified were shown to cause loss of function; given that IL17RD is an inhibitor, the mutations increase FGF8 signaling in vitro. This might appear counterintuitive given that CHH-associated loss-of-function mutations in FGF8, FGFR1, KAL1, and HS6ST1 described thus far lead to decreased FGF8 signaling. Nevertheless, Il17rd À/À mice (which display increased FGF8 activity) and IL17RD-overexpressing chickens (which display decreased FGF8 activity) both show defects in the cochlear nucleus and dysfunction of the auditory brainstem. 25 Moreover, complete elimination or overexpression of FGF8 increased apoptosis in olfactory progenitor cells, whereas a lesser decrease in functional FGF8 expression resulted in cell survival, suggesting nonlinear dosage effects. 68 All studied individuals with IL17RD mutations have KS, and the fact that six out of eight (75%) have hearing loss suggests a frequency much higher than the 6% reported previously. 69 It appears that either biallelic IL17RD mutations or an additional mutation in another locus is needed to cause KS or hearing loss. The hearing-loss phenotype is consistent with the fact that IL17RD is a powerful inhibitor of FGF8 signaling: acting through FGFR1c, FGF8 is a morphogen for otic development in both chickens and mice. 7, 70 In zebrafish, the injection of sef (also called il17rd) mRNA into embryos produces a phenotype similar to that of fgf8 deficiency, including a smaller otic vesicle. 16 Further, Il17rd À/À mice or IL17RD-overexpressing chickens exhibit auditory brainstem defects. 25 Thus, IL17RD appears to be critical not only for GnRH neuron ontogeny but also for the normal development of the auditory system by modulating FGF signaling. The present study was not specifically designed to investigate the frequency of IL17RD mutations among CHH individuals with hearing loss; after the identification of IL17RD as a locus for CHH with this particular subphenotype, a next logical step is to screen a larger cohort of CHH individuals with hearing loss for mutations in IL17RD. Moreover, because CHH is usually only diagnosed at or after the age of puberty, it would be interesting to test prepubertal individuals with congenital hearing loss for this gene, especially those with other clinical manifestations suggestive of KS (i.e., cryptorchidism, anosmia, skeletal defects, etc.). The second-highest ranked gene was FGF17, which emerged as the gene encoding the second-most critical FGFR1c ligand for GnRH neuron ontogeny. This link is based on (1) the decreased binding of FGF17 to the KSassociated c.1025T>C (p.Leu342Ser) FGFR1c mutant, (2) the identification of loss-of-function FGF17 mutations in CHH individuals with severe associated skeletal anomalies, and (3) the demonstration that Fgf17 is a member of the Fgf8 synexpression group in the medial aspect of the olfactory placode in E10.5 mice, where its expression requires Fgf8. Mice lacking FGF17 have cerebellar defects and selective reduction in the size of the dorsal frontal cortex, consistent with a role similar to that of FGF8 in patterning the neocortical map. However, the olfactory bulbs seem unaffected in FGF17-deficient mice; thus, FGF17 appears to be a less powerful morphogen than FGF8. 20 Similarly to that of other FGF subfamilies, the expansion of the FGF8 group has most likely been contributed to by geneduplication events throughout evolution. The high conservation of FGF17 suggests that, in addition to providing functional redundancy with FGF8, it might have evolved unique roles for each subfamily member. In this regard, it is interesting that in adult zebrafish, Fgf8 signaling is restricted to the periventricular area whereas Fgf17 is widely expressed in the hypothalamus 21 because this suggests a different function for Fgf17, such as a potential role in GnRH neuron survival in adulthood. The mutations in DUSP6, SPRY4, and FLRT3 were not functionally characterized in this study. These members of the FGF8 synexpression module play pleitropic roles in embryogenesis and adulthood. DUSP6 is a dual-specificity protein phosphatase, which dephosphorylates and thereby inactivates MAP kinases. 32 In rat PC12 cells, 36 and acts as a repulsive guidance cue for UNC5-positive neurons in mice. 75 The present identification of mutations in DUSP6, SPRY4, and FLRT3 in CHH individuals might offer new opportunities for studies of these genes in GnRH biology. Studying FGFR1 mutations in CHH has been pivotal in challenging the traditional monogenic view of this disorder and in transitioning toward more complex genetic models. 5, 39, 53 Proof of concept for the oligogenic paradigm has been provided by model organisms; for example, Fgfr1 þ/À Fgf8 þ/À double heterozygous mice show an additive loss of GnRH neurons, 76 and Il17rd and Spry2 synergize in zebrafish to regulate the expression of Gbx2 in the mid-hindbrain region. 77 The present identification of five additional genes with mutations in CHH expands not only the percentage of cases with a known genetic cause but also the percentage of individuals with evidence of oligogenicity: among the 17 genes analyzed, oligogenicity accounts for 19% of individuals compared to 10% in prior work examining eight CHH loci. 39 The updated frequency of oligogenicity (19%) considers only the one-third of individuals (124/350) found to harbor at least one mutation; we therefore anticipate that the true frequency of oligogenicity in CHH is substantially higher and that our estimates will better approach it as mutations are identified in further loci, especially through application of next-generation-sequencing technologies to large CHH cohorts.
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